Disclosed is a chewable antibiotic veterinary formulation comprising: an antibiotic, selected from group consisting of beta lactams, semisynthetic penicillins, bacitracin, cephalosporins, quinolones, fluorinated quinolones, polymyxin, tetracyclines, chloramphenicol, aminoglycosides, nalidixic acid, rifamycins, sulfonamides, amikacin, aminosalicyclic acid, amoxicillin, amoxicillin and clavulanate potassium, ampicillin, bacampicillin, bacitracin, capreomycin, carbenicillin, carbenicillin indanyl s...

Use of low dose streptozocin in the preparation of an animal model for screening drugs for treatment of autoimmunity type 1 diabetes is disclosed is disclosed, in which the streptozocin is administrated intravenously in the dose of 15-30 mg/kg per time for 5 days and administered again on the 7th days and 14th days after last time of offering drug. A method for preparing rhesus monkey model of autoimmunity type 1 diabetes and autoimmunity type 1 diabetes animal models obtained are also disclosed...

The invention relates to use of derivative of 14-dihydropyridine 26-dimethyl-35-(2-dipropoxyetoxycarbonyl)-4-(2-difluorometoxy)phenyl-14-dihydropyridine (Cerebrocrast). The compound may be used alone or in combination with other antidiabetic agents to reduce diabetic neuropathy and to prevent complications of diabetes (for example ulcers gangrenes sexual dysfunction sudden death).

Genes associated with Type II Diabetes Mellitus (T2DM) are identified and screening methods to identify chemical compounds that act on those targets for the treatment of T2DM or its associated pathologies are discussed. The use of EP3 antagonist was found to affect blood glucose levels in mice fed a high-fat diet and made insulin deficient by streptozocin injection.